Device Vascular

Prelude Introducers

Payments companies reported to CMS as associated with Prelude Introducers. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$29Kassociated payments (2023-2025)
46clinicians with associated payments
1company reporting

By year

2023 $8,702
2024 $1,936
2025 $18K

Payments reported as associated with Prelude Introducers, per program year, as reported to CMS.

Who makes it

Specialties most often involved

General Practice $20K
Vascular & Interventional Radiology $4,494
Cardiovascular Disease $848
Pediatric Cardiology $650
Vascular Surgery $342
Interventional Cardiology $283

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Prelude Introducers

These are the largest totals companies reported as associated with Prelude Introducers. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Ryan Lewis South Jordan, UT General Practice $19,912.50
Peter Hathaway Farmington, UT Vascular & Interventional Radiology $4,125.00
Adhir Shroff Chicago, IL Cardiovascular Disease $650.00
Howaida El Said San Diego, CA Pediatric Cardiology $650.00
Georges Haidar Elk Grove Village, IL Vascular Surgery $200.00
Joseph Muhlestein Billings, MT Clinical Cardiac Electrophysiology $150.53
Carson Webb Anchorage, AK Interventional Cardiology $125.00
Brian Scully Anchorage, AK Cardiovascular Disease $125.00
John Fischer Sugar Land, TX Vascular & Interventional Radiology $88.51
Raymond Schaerf Burbank, CA Thoracic Surgery (Cardiothoracic Vascular Surgery) $61.33

Prescribed Prelude Introducers?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.